Both ligand-dependent and ligand-independent activation of estrogen receptor (ER)a is modulated by receptor phosphorylation and results in activation of the ERa-dependent pathways that are involved in endometrioid endometrial cancer (EEC) pathogenesis. It is also known that the mammalian target of rapamycin (mTOR) ⁄ p70 S6 kinase 1 (S6K1) and MAPK ⁄ p90 ribosomal S6 kinase (RSK) signaling pathways coordinately regulate phosphorylated-ERa at Ser 167 (p-Ser 167 -ERa). However, the expression of p-Ser 167 -ERa in EEC and its prognostic role in ECC is largely unexplored. The purpose of the present study was to investigate the expression of p-Ser
Both ligand-dependent and ligand-independent activation of estrogen receptor (ER)a is modulated by receptor phosphorylation and results in activation of the ERa-dependent pathways that are involved in endometrioid endometrial cancer (EEC) pathogenesis. It is also known that the mammalian target of rapamycin (mTOR) ⁄ p70 S6 kinase 1 (S6K1) and MAPK ⁄ p90 ribosomal S6 kinase (RSK) signaling pathways coordinately regulate phosphorylated-ERa at Ser 167 (p-Ser 167 -ERa). However, the expression of p-Ser 167 -ERa in EEC and its prognostic role in ECC is largely unexplored. The purpose of the present study was to investigate the expression of p-Ser
167
-ERa in ECC and its relationship with prognosis. Immunohistochemical staining of primary EEC surgical specimens (n = 103) was carried out using antibodies specific for p-Ser E ndometrial cancer (EC) is the most common gynecological cancer and is thought to be estrogen-related. The estrogen receptor (ER) is a biological target for EC that has attracted considerable attention over the years. For many EC patients, particularly those with endometrial endometrioid cancer (EEC), which are tumors that express high levels of the ER, the observed response rates to hormonal agents such as progestins, antiestrogens, and aromatase inhibitors have not been satisfactory; indeed, many patients with advanced or refractory disease eventually develop resistance to this type of therapy and median survival is short at 7-12 month. (1, 2) Both ligand-dependent and ligand-independent activation of the ERa is modulated by receptor phosphorylation, and receptor phosphorylation is enhanced by ligand binding. (3) The major phosphorylation sites of ERa reside in the N-terminal domain at serines 104, 105, 118, and 167. Phosphorylation at Ser 167 was shown to be important in receptor binding to DNA. (3) In breast cancer, which is also an estrogen-related tumor, one mechanism by which resistance to hormone therapy develops is through phosphorylation of ERa at Ser 167 (p-Ser 167 -ERa), a modification that allows the receptor to function in an estrogen-independent manner. (4) It has also been reported that two signaling pathways, mammalian target rapamycin (mTOR) ⁄ p70 S6 kinase 1 (S6K1) and MAPK ⁄ p90 ribosomal S6 kinase (RSK), coordinately regulate p-Ser 167 -ERa and the development of resistance, which can serve as a prognostic marker for breast cancer. (5, 6) Previously published in vivo data suggest that Akt is phosphorylated leading to active p-Ser
-ERa and resulting in activation of ERa-dependent pathways involved in EEC pathogenesis. (7) However, to the best of our knowledge, there are no published reports regarding the influence of p-Ser 167 -ERa and mTOR ⁄ S6K1 and MAPK ⁄ RSK activity on outcomes in EEC patients.
The current study was designed to investigate correlations between p-Ser 167 -ERa levels in EEC with clinicopathological features, disease outcomes, and levels of phosphorylated mTOR ⁄ S6K1 and phosphorylated MAPK ⁄ RSK (p-mTOR ⁄ p-S6K1 and p-MAPK ⁄ p-p90RSK, respectively), as determined by examination of medical records and by immunohistochemical analysis.
Materials and Methods
Patients. The study group comprised 103 EEC patients who underwent total abdominal or radical hysterectomy plus bilateral salpingo-oophorectomy with or without lymphadenectomy during a 5-year period at the University of Fukui Hospital (Fukui, Japan) ( Table 1) . Clinicopathological characteristics and follow-up data were obtained from the subjects' medical records. Staging, histology, and grading criteria were based on the 2009 International Federation of Gynecology and Obstetrics surgical staging classification. Definitive diagnosis was determined by postoperative histopathology and all specimens were evaluated by subsequent immunohistochemical analysis.
Patients with deep myometrial invasion, cervical involvement, special histology (such as undifferentiated adenocarcinoma), or lymph-node metastasis were treated with four to six rounds of postoperative adjuvant chemotherapy consisting of 180 mg ⁄ m 2 paclitaxel and carboplatin, according to Chatelut's formula (area under the curve = 5 mg ⁄ mL ⁄ min). No patient was treated with hormone therapy, whether past or current. All patients were evaluated for disease recurrence for at least 2 years by annual physical examination and pap smear of the vaginal vault. In addition, diagnostic imaging (including ultrasonography, computed tomography, and ⁄ or MRI) was carried out every 3-6 month along with analysis of tumor markers. This study was approved by the institutional review board of the University of Fukui Hospital and written informed consent was obtained from all patients.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue was immunohistochemically stained using the avidinbiotin-peroxidase complex technique with an LSAB kit (Dako, Glostrup, Denmark). (8) Sections (2.5-lm thick) were dewaxed in xylene for 15 min three times, dehydrated in alcohol, and subjected to antigen retrieval in a pressure cooker for 15 min in 10 mM sodium citrate buffer (pH 6.0). After cooling, sections were washed three times in PBS (pH 7.2). Endogenous peroxidase activity was blocked by immersion in 3% hydrogen peroxide for 5 min. Non-specific binding of primary antibodies was blocked by incubating sections with diluted (Dako Protein Block Serum-Free) for 10 min at room temperature. Samples were then incubated overnight with primary antibodies to the following proteins, diluted in PBS: ERa Sections were then counterstained with Mayer's acidic hematoxylin and washed multiple times in alcohol (70-100%). After xylene treatment, sections were covered until used.
Sections from human colon and breast cancers were used as positive controls and, for negative controls, incubation with the primary antibody was omitted. The intensity and distribution of p-Ser 167 -ERa, p-MAPK, p-p90RSK, p-mTOR, and p-S6K1 staining was evaluated using a semiquantitative method (IRS score) as previously described, (8) and was calculated as follows: IRS = ΣSI 9 PP, where SI is the optical stain intensity (graded 0, no; 1, weak; 2, moderate; 3, strong staining) and PP is the degree of positively stained cells (defined as 0, no staining; 1, <10%; 2, 11-50%; 3, 51-80%; 4, >81%). Those IRS scores greater than 6 (IRS ≥6) were defined as "positive", and less than 5 (IRS 0-5) as "negative". Immunostaining was scored by two independent observers (T. K. and A. S.) who are specialists in gynecological pathology. Discrepancies of more than two points in either optimal stain intensities or in the degree of positively stained cells were rare. However, if such discrepancies occurred, these slides were again evaluated by both observers. If the observers could not reach agreement on evaluation of immunostainings, these cases were excluded from this analysis. Ultimately, staining data for p-Ser 167 -ERa, p-MAPK, p-p90RSK, and p-mTOR were available for 103 patients and staining data for p-S6K1 were available for 98 patients. p-S6K1 N P P-value N P P-value N P P-value N P P-value N P P-value N P P-value N P P-value Statistical analysis. The chi-square-test was used to test possible associations between clinicopathological factors and pSer 167 -ERa, p-MAPK, p-p90RSK, p-mTOR, or p-S6K1. This test was also used to assess correlations between p-Ser 167 -ERa and p-MAPK, p-p90RSK, p-mTOR, or p-S6K1 levels. KaplanMeier curves were plotted to assess the effects of p-Ser 167 -ERa level on relapse-free survival (RFS). Survival curves were compared using the log-rank test. P-values of 0.05 or less were considered statistically significant. Multivariate a proportional Cox models were used to assess the prognostic significance of p-Ser 167 -ERa, p-MAPK, p-p90RSK, p-mTOR, and p-S6K1 levels, and their relationship to several clinicopathological factors. Statistical analysis was carried out using SPSS for Windows 14.0 (SPSS Inc., Chicago, IL, USA).
Results

Phosphorylated Ser
167 -ERa was observed in the nuclei and cytoplasm of EEC cells (in 10.7% and 12.6% of the cells, respectively) (Fig. 1) , as was p-mTOR (in 21.4% and 51.5% of the cells, respectively). Phosphorylated MAPK, p-p90RSK, and p-S6K1 were observed only in the cytoplasm (in 16.5%, 44.7%, and 55.3% of the cells, respectively).
There was a positive correlation between nuclear and cytoplasmic levels of p-Ser 167 -ERa (P = 0.001) and p-mTOR (P = 0.024). Nuclear p-Ser 167 -ERa was positively correlated with p-MAPK and p-S6K1, and cytoplasmic p-Ser 167 -ERa was positively correlated with p-MAPK; in all cases correlations were significant. Cytoplasmic p-Ser 167 -ERa was marginally correlated with cytoplasmic p-mTOR (P = 0.05). There was significant correlation between p-S6K1 and p-p90RSK, and between cytoplasmic p-mTOR and p-p90RSK (Table 2) .
Nuclear p-Ser 167 -ERa levels tended to be higher in patients with advanced disease, but this result was not significant. Cytoplasmic p-Ser 167 -ERa, cytoplasmic p-mTOR, and p-MAPK were not correlated with any clinicopathological factors (Table 3) . However, p-p90RSK was positively correlated with stage (P = 0.004) and lymphovascular space invasion (LVSI) (P = 0.017), as was p-S6K1 (P = 0.003 and P = 0.041, respectively). Nuclear p-mTOR was positively correlated with grade (P = 0.002).
Patients positive for nuclear p-Ser 167 -ERa had significantly shorter RFS (P < 0.01) (Fig. 2a) . Although not significant, patients positive for cytoplasmic p-Ser 167 -ERa tended to have shorter RFS (Fig. 2b) than those negative for the same (P = 0.261). Patients were classified for RFS analysis into the following four subgroups, according to p-Ser 167 -ERa level: group A, patients negative for cytoplasmic and nuclear p-Ser 167 -ERa; group B, patients positive for cytoplasmic p-Ser 167 -ERa only; group C, patients positive for nuclear p-Ser 167 -ERa only; and group D, patients positive for cytoplasmic and nuclear p-Ser 167 -ERa (Fig. 3) . Of the four groups, RFS was shortest in patients positive for cytoplasmic and nuclear p-Ser 167 -ERa (group D) (P < 0.01), and was the most favorable for patients negative for both (group A).
The prognostic relevance of levels of p-Ser 167 -ERa, mTOR, p-MAPK, p-p90RSK, and p-S6K1 was analyzed using a multivariate proportional hazards model adjusted for established clinical prognostic factors; depth of tumor invasion, LVSI, histological grade, and stage (Table 4) . Histological grade and LVSI were independent prognostic factors for RFS (hazard ratio [HR] = 38.285; 95% confidence interval [CI], 1.882-778.7; P = 0.018; and HR = 6.567; 95% CI, 1.087-39.676; P = 0.040, respectively), but nuclear p-Ser 167 -ERa level was not independent (HR = 6.707; 95% CI, 0.419-107.406; P = 0.179). In addition, there were no correlations between nuclear p-mTOR and recurrence site. 
Discussion
In this study we identified that, in EEC, nuclear p-Ser 167 -ERa is the result of cooperation between mTOR ⁄ S6K1 and MAPK ⁄ RSK signaling pathways, and indicates development of advanced disease carrying a poor prognosis. Therefore, increased nuclear p-Ser 167 -ERa may play a pivotal role in the neoplastic process, and may be a marker indicating poor prognosis; this is the opposite of the situation seen in breast cancer patients. (9, 10) Yamashita et al. (9) indicated that patients whose primary breast tumors extensively expressed p-Ser 167 -ERa responded significantly better to endocrine therapy and had better survival than did other patients. A breast cancer study carried out by Jian et al. also showed that the level of p-Ser 167 -ERa was strongly associated with p-p90RSK and p-MAPK, and seemed to be indicative of better prognosis. Interestingly, they reported that there was no association between human epidermal growth factor receptor-2 (HER2)-positive status and p-Ser 167 -ERa, nor were the activities of p-MAPK or p-p90RSK associated with HER2 status. However, HER2 status was associated with phosphorylated AKT (p-AKT), and p-AKT was also associated with p-Ser 167 -ERa, and with a greater likelihood of relapse and death due to cancer. Although p-AKT was not associated with disease-free survival, p-AKT positivity was associated with a reduction in overall survival. They suggested that p-p90RSK and p-MAPK, rather than p-AKT, may mediate the phosphorylation of p-Ser 167 -ERa in breast cancer cells, and that p-AKT is instead involved in regulating other cellular processes that lead to reduced patient survival. (10) The statement that p-AKT can potentially induce the phosphorylation of p-Ser 167 -ERa appears to contradict the earlier statement that the authors of the study suggested that it was p-p90RSK and p-MAPK, rather than p-AKT, that may mediate the phosphorylation of p-Ser 167 -ERa in breast cancer cells. To our knowledge, there have only been a few reports of studies in which the relationship between p-ERa Ser 167 and EEC have been explored. Vilgelm et al. (7) indicated that the loss of phosphatase and tensin homologue deleated on chromosome ten (PTEN) and AKT activation results in a Ser 167 phosphorylation-dependent enhancement of ERa transcriptional activity that is independent of estrogen and plays a pivotal role in the neoplastic process. Shah et al. (3) identified a connection between the ER coactivators of steroid receptor coactivator (Src) kinase and p-ERa Ser 167 through activation of the phosphatidylinositol 3-kinase (PI3K) ⁄ AKT pathway, which, in turn, potentiates tamoxifen agonist action. These data supported the idea that Ser 167 phosphorylation of the ER through activation of the PI3K ⁄ AKT pathway in the endometrium is an important process.
Recent molecular profiling has shown that increased PI3K ⁄ AKT ⁄ mTOR signaling is associated with aggressive disease and poor prognosis, irrespective of endometrial cancer tumor. (11) A major downstream effector of AKT is mTOR complex1 (mTORC1); its downstream targets, such as ribosomal S6K1, control protein synthesis. Another mTOR complex, mTORC2, participates in the activation of AKT. In our previous study of a series of 82 patients with ECC, we reported that nuclear mTORC1 was significantly elevated in poorly differentiated tumors with lymph node involvement and in patients with shorter survival. (8) In the present study, immunohistochemical evaluation of the expression of p-S6K1 indicated that it was positively correlated with LVSI. Lymphovascular space invasion includes lymphatic vessel invasion and blood vessel invasion, thought to be the beginnings of lymphogenous and hematogenous metastases, respectively. Koskas et al. (12) suggested that LVSI should be considered as an independent risk factor for lymph node metastasis. It is therefore a reasonable finding that overexpression of p-S6K1 was observed in the present LVSI cases.
Signaling of mTORC1 is also involved in cross-talk with MAPK signaling. (11) The corresponding effectors of these pathways, S6K1 and RSK respectively, have been shown to converge on a common set of targets, most notably in control of protein translation. (13) (14) (15) In this study, we identified nuclear p-Ser 167 -ERa as a recipient of coordinated phosphorylation inputs from MAPK and mTOR and showed that nuclear p-Ser 167 -ERa might be related to the biological behavior of ECC. These findings are similar to results reported in breast cancer; Yamnik et al. (5, 6) reported that mTOR ⁄ S6K1 and MAPK ⁄ RSK coordinately regulate p-Ser 167 -ERa and the development of resistance, which can serve as a prognostic marker for breast cancer.
In conclusion, we showed that, in EEC, nuclear p-Ser 167 -ERa was strongly positively correlated with p-MAPK and p-S6K1. The coordinate action of mTOR ⁄ S6K1 and MAPK ⁄ RSK pathways provide a strong stimulus for EEC tumor growth, and may contribute to the development of advanced stages of cancer with poor prognosis. We suggest that dual inhibition of the mTOR ⁄ S6K1 and MAPK ⁄ RSK signaling pathways, which lead to ERa activation and stimulation of EEC development, may result in better clinical responses in advanced EEC patients. 
